Clearbridge Investments, LLC Voyager Therapeutics, Inc. Transaction History

Clearbridge Investments, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$3.94 - $5.44 $5.45 Million - $7.53 Million	-1,383,414 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$4.61 - $9.04 $14,987 - $29,389	-3,251 Reduced 0.23%	1,383,414 $6.52 Million
Q4 2020 Feb 10, 2021	BUY	$7.15 - $12.28 $1,808 - $3,106	253 Added 0.02%	1,386,665 $9.92 Million
Q3 2020 Nov 12, 2020	BUY	$10.01 - $13.75 $81,091 - $111,388	8,101 Added 0.59%	1,386,412 $14.8 Million
Q2 2020 Aug 14, 2020	BUY	$8.05 - $14.21 $1.37 Million - $2.41 Million	169,636 Added 14.03%	1,378,311 $17.4 Million
Q1 2020 May 15, 2020	BUY	$6.8 - $14.66 $1.34 Million - $2.88 Million	196,342 Added 19.4%	1,208,675 $11.1 Million
Q4 2019 Feb 14, 2020	SELL	$12.82 - $16.85 $2.91 Million - $3.82 Million	-226,628 Reduced 18.29%	1,012,333 $13.7 Million
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $14 Million - $24.3 Million	859,988 Added 226.93%	1,238,961 $21.3 Million
Q2 2019 Aug 14, 2019	SELL	$19.18 - $27.88 $19,180 - $27,880	-1,000 Reduced 0.26%	378,973 $0
Q1 2019 May 15, 2019	BUY	$8.0 - $19.66 $3.04 Million - $7.46 Million	379,565 Added 93030.64%	379,973 $7.27 Million
Q2 2018 Aug 14, 2018	SELL	$16.76 - $23.92 $1.12 Million - $1.6 Million	-67,092 Reduced 99.4%	408 $8,000
Q1 2018 May 15, 2018	SELL	$16.16 - $31.31 $8,823 - $17,095	-546 Reduced 0.8%	67,500 $1.27 Million
Q4 2017 Feb 14, 2018	BUY	$12.26 - $25.88 $809,074 - $1.71 Million	65,993 Added 3214.47%	68,046 $1.13 Million
Q3 2017 Nov 14, 2017	BUY	$8.37 - $20.59 $17,183 - $42,271	2,053	2,053 $42,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $207M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearbridge Investments, LLC with notifications on news.